Guselkumab, a selective antagonist of IL-23, went head to head with adalimumab in a year-long phase 2 trial of 293 patients with moderate to severe plaque psoriasis. A quick synopsis of the results here.
Difficult diagnosis, overlap with other conditions, lack of objective signs, the absence of proven treatment. . . these reviews of chronic fatigue syndrome filter and summarize the most rigorous evidence available.
The VirScan system can measure a subject's exposure to all known human viruses. This will enable population studies that find any associations with a particular viral infection for every rheumatological disease. And it only costs about $25 per blood sample.